100% Original Factory Sofosbuvir - Sacubitril Hemicalcium – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our pursuit and firm aim should be to "Always fulfill our buyer requirements". We carry on to produce and structure top-quality excellent solutions for equally our aged and new consumers and accomplish a win-win prospect for our consumers as well as us for Celecoxib Supplier, Boceprevir Telaprevir, Ezetimibe, To significantly improve our service quality, our company imports a large number of foreign advanced devices. Welcome clients from home and abroad to call and inquire!
100% Original Factory Sofosbuvir - Sacubitril Hemicalcium – CPF Detail:

    沙库比曲半钙盐 Sacubitril Hemicalcium 1369773-39-6 In-House
    沙库比曲钠盐 149690-05-1 In-House
    LCZ-4 1426129-50-1 In-House
    LCZ-7 1012341-48-8 In-House
    LCZ-8 1012341-50-2 In-House
    LCZ-9 149690-12-0 In-House

 

Background

AHU-377 hemicalcium salt is a hemicalcium salt form of AHU-377. It is an inhibitor of neprilysin with IC50 value of 5 nM [1].

AHU-377 and the angiotensin II AT1 receptor antagonist valsartan compose LCZ696 in a 1:1 molar ratio. LCZ696 is an angiotensin receptor neprilysin inhibitor. It can reduce blood pressure and may be a novel drug for the treatment of heart failure. AHU-377 is a pro-drug, it can be converted by enzymatic cleavage of the ethyl ester into the active form LBQ657. It is reported that AHU-377(30 and 100 mg/kg, PO) can cause antihypertensive effect in a dose-dependent manner in DAHI-SS rats. But in the DOCA-salt hypertensive rats, it shows a weak reduction [2, 3].

References:
[1] Ksander GM, Ghai RD, deJesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12; 38(10):1689-700.
[2] Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7.
[3] Laxminarayan G Hegde, Cecile Yu, Cheruvu Madhavi et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacology 2011, 11(Suppl 1):P33.

Chemical structure

Sacubitril Hemicalcium

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation


Product detail pictures:

100% Original Factory Sofosbuvir - Sacubitril Hemicalcium  – CPF detail pictures


Related Product Guide:

We hold strengthening and perfecting our items and repair. At the same time, we get the job done actively to do research and progress for 100% Original Factory Sofosbuvir - Sacubitril Hemicalcium – CPF , The product will supply to all over the world, such as: Angola, Nairobi, Miami, Now, we professionally supplies customers with our main products And our business is not only the "buy" and "sell", but also focus on more. We target to be your loyal supplier and long-term cooperator in China. Now, We hope to be the friends with you.
  • The factory workers have a good team spirit, so we received high quality products fast, in addition, the price is also appropriate, this is a very good and reliable Chinese manufacturers.
    5 Stars By Eileen from kazakhstan - 2018.06.30 17:29
    Problems can be quickly and effectively resolved, it is worth to be trust and working together.
    5 Stars By Ann from Turin - 2017.05.31 13:26
    Write your message here and send it to us